<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="149562">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01767688</url>
  </required_header>
  <id_info>
    <org_study_id>3102-031</org_study_id>
    <nct_id>NCT01767688</nct_id>
  </id_info>
  <brief_title>A Pharmacokinetic Study of MK-3102 in Participants With Impaired Hepatic Function (MK-3102-031)</brief_title>
  <official_title>An Open-Label, Single-Dose Study to Investigate the Pharmacokinetics of MK-3102 in Patients With Impaired Hepatic Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate and compare the pharmacokinetics of a single 25-mg dose of
      MK-3102 in participants with moderate hepatic impairment and matched healthy participants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) from Hour 0 to Infinity (AUC0-∞)</measure>
    <time_frame>From predose (Hour 0) up to 168 hours post dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration versus time curve from Hour 0 to 168 hours  after dosing (AUC0-168h)</measure>
    <time_frame>From predose (Hour 0) up to 168 hours post dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>From predose (Hour 0) up to 168 hours post dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration at 168 hours after dosing (C168h)</measure>
    <time_frame>168 hours post dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum observed plasma drug concentration (Tmax)</measure>
    <time_frame>From predose (Hour 0) up to 168 hours post dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal phase half-life (t½)</measure>
    <time_frame>From predose (Hour 0) up to 168 hours post dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants experiencing adverse events (AEs)</measure>
    <time_frame>Up to 14 days post dose</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants discontinued from study due to AEs</measure>
    <time_frame>Up to 14 days post dose</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Moderate Hepatic Impairment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Matched Control Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-3102</intervention_name>
    <description>Single dose of 25 mg of MK-3102 (1 x 25 mg capsule) administered orally on Day 1.</description>
    <arm_group_label>Moderate Hepatic Impairment Group</arm_group_label>
    <arm_group_label>Healthy Matched Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Impaired Hepatic Function Participants:

          -  A diagnosis of:

               1. Chronic (&gt; 6 months) hepatic insufficiency

               2. Stable (no acute episodes of illness within the previous 2 months due to
                  deterioration in hepatic function) hepatic insufficiency with features of
                  cirrhosis due to any etiology

          -  Score on the Child-Pugh Scale of 7 to 9 (moderate hepatic insufficiency)

          -  Estimated creatinine clearance (CLCr) &gt; 60 mL/min or glomerular filtration rate
             (eGFR) ≥ 60 mL/min/1.73 m^2

        Both Impaired Hepatic Function and Healthy Participants:

          -  In general good health

          -  Continuous non-smokers or moderate smokers for at least 3 months prior to study start

          -  Body Mass Index ≤39 kg/m^2

          -  Females of reproductive potential must have a negative pregnancy test and agree to
             use acceptable birth control method(s) or remain sexually inactive throughout study

          -  Non-vasectomized male patients must agree to use acceptable birth control method(s)
             or abstain from sexual intercourse during the trial and for 3 months after the study

        Exclusion Criteria:

        Healthy Participants:

          -  History or presence of alcoholism within the past 2 years

          -  Presence of hepatitis B virus (HBV) or hepatitis virus C (HVC)

        Both Impaired Hepatic Function and Healthy Participants:

          -  History or presence of drug abuse within the past 2 years

          -  History or presence of human immunodeficiency virus (HIV)

          -  History or presence of significant cardiovascular, pulmonary, renal, hematologic,
             gastrointestinal (other than hepatic impairment), endocrine, immunologic,
             dermatologic, or neurological disease

          -  Use of any medication or substance (including prescription or over the counter,
             health supplements, natural or herbal supplements) which cannot be

        discontinued at least 14 days prior to the study start and throughout the study

          -  Has been on a special diet within 28 days prior to the study start

          -  Blood donation within 56 days or plasma donation within 7 days prior to study start

          -  Participation in another clinical trial within 28 days of study start

          -  Women who are pregnant or nursing
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 28, 2014</lastchanged_date>
  <firstreceived_date>January 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Diabetes Mellitus, Type 2</keyword>
  <keyword>Glucose Metabolism Disorders</keyword>
  <keyword>Metabolic Diseases</keyword>
  <keyword>Endocrine System Diseases</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
